[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$frxBPn8rcF7vCCHdaio3jITt7g02gEJUVCihxo6dgpPQ":8,"$f5n4QmcwHgdbF8MGkCARIh2Pui2F31nFejir2GxZ7b-w":60,"$f-NjS_Kjg90Ic83oqzENdaPF7gPNtR6ncnUYdolT3NxI":61,"$fgwdYP8hh4-ZwBNUCl2n0iEvZQaLN7ZVKKIZ6wXDlu78":65},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":59},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"roleType":17,"adept":18,"hospital":19,"department":20,"postsTitle":21,"materialTotal":17,"videoTotal":22,"isConcern":7,"title":23,"coverVertical":24,"coverAcross":25,"directionMarker":26,"description":27,"vid":28,"time":29,"mediaType":30,"views":31,"likes":17,"isThumbsUp":7,"isCollection":7,"collections":17,"createTime":32,"seoTitle":33,"seoKeywords":34,"seoDescription":35,"shelvesTime":36,"menus":37,"menuId":39,"type":26,"quality":56,"commentCount":17,"isComment":30,"deviceType":57,"url":58},7421,864010,[],"https://ystcdn.venuertc.com/medical/ystApp/jcn4OOPC5LtCtr0GP8pVcox0NpODQ4Hk.png","庞亚飞",0,"擅长系统性血管炎、成人Still病、白塞病以及反应性关节炎的诊治","上海市宝山区中西医结合医院","风湿免疫科","副主任医师",3,"银屑病共病（关节炎、心血管、三高）","https://cdn.yishi-tong.com/console/3/JpHbFEhRLIMxxUoLNHAS6mmRi7c6BYkU.png","https://cdn.yishi-tong.com/console/3/1kjli9JiA-gUCfN_gwDaM5pGnXR6zO4J.png",2,"大家好，我是XX医生，今天我们要深入探讨一个话题——银屑病共病，特别是与关节炎、心血管疾病以及三高的关系。这个看似只影响皮肤的疾病，其实背后隐藏着更大的健康威胁。\n\n一、银屑病与常见共病的关系\n\n银屑病关节炎（PsA）是一种与银屑病相关的炎性关节病，常表现为关节疼痛、肿胀、压痛、僵硬和运动障碍。该病可发生于任何年龄，高峰年龄为30至50岁。大约75%的患者在关节炎发作前已出现皮疹，约15%的患者关节炎与皮疹同时出现，还有10%的患者关节炎出现在皮疹之后。这种关节炎易复发，晚期可能导致关节强直和残废。\n\n而心血管疾病是银屑病患者的另一大威胁。由于银屑病本质是一种自身免疫性疾病，控制不佳可能导致全身器官和系统的受累。特别是心血管系统，研究表明，银屑病患者患动脉粥样硬化的风险几乎是非银屑病患者的1倍。这种风险增加可能与系统性炎症、血脂异常和代谢综合征有关。炎症因子的释放可能间接影响心血管系统的功能，导致动脉内膜平滑肌细胞、巨噬细胞及T淋巴细胞局部迁移，最终形成动脉粥样硬化。同时银屑病患者发生冠心病、心肌梗死和高血压的风险也显著增加。\n\n此外“三高”也是银屑病患者常见的共病。炎症介质在银屑病患者体内的过度释放可能干扰胰岛素的分泌和利用，影响血糖的调节机制，从而增加高血糖和糖尿病的风险。同时，慢性炎症状态还可能导致脂质代谢紊乱，使胆固醇等血脂物质在体内过多产生，进而导致高血脂。而血管内皮功能异常和血管弹性下降则可能引发高血压。这些代谢异常不仅进一步加剧心血管疾病的风险，还可能导致肥胖和整体健康状况的恶化。\n\n因此面对银屑病共病，预防共病的发生与管理银屑病的进一步恶化为重中之重。\n\n二、银屑病共病的预防与管理\n\n首先，银屑病的积极治疗至关重要。目前生物制剂因其低副作用与高准确性，已成为我国治疗银屑病的系统用药，其地位在2023版指南中得到了修改与提高。此外有研究提出，在治疗银屑病共病共病患者时IL-17i为一线选择。而我国首个本土自研的中重度银屑病创新药——夫那奇珠作为一种靶向人IL-17A的单克隆抗体，为银屑病关节炎的治疗提供了新的选择。目前其单抗注射液已获NMPA批准上市，其安全性与已获批的依奇珠单抗和司库奇尤单抗相当，没有发现新的安全性信号。\n\n此外药物三期临床数据显示，其治疗12周实现PASI 75（银屑病面积和严重性指数改善75%以上）高达93.6%，PASI 100（即皮损完全清除）应答率达36.6%。因此患者在发现患银屑病时，应积极配合医生的治疗方案，不要过度恐惧，我们的治疗选择在以后也会越来越多样化。\n\n其次，为了预防共病的发生与及时干预，银屑病患者应积极观察疾病发展。轻度银屑病患者应每年进行筛查，重度患者应每半年筛查一次，以监测相关共病的发生，并进行及时的干预。此外，健康的生活习惯也是必不可少的。建议患者保持低盐、低脂、低糖的饮食习惯，适度运动，戒烟限酒，并学会合理排解压力。\n\n通过本次的介绍，希望大家在面对银屑病时能有正确的认识，积极参与治疗、预防共病的发生。","v0247cg10004d2v8gqqljhtc284eagbg",203,1,518,"2025-07-03 14:49:03","银屑病共病管理：关节炎、心血管疾病及三高防治指南  ","银屑病共病, 银屑病关节炎, 银屑病心血管风险, 银屑病三高管理, 银屑病并发症预防  ","了解银屑病与关节炎、心血管疾病及高血压/高血脂/高血糖的共病关联，获取科学防治建议与健康管理方案，降低并发症风险，提升生活质量。","2025-07-07 22:20:00",[38],{"menuId":39,"menuName":40,"parentId":17,"orderNum":22,"path":41,"component":42,"isFrame":43,"isCache":44,"menuType":45,"visible":30,"status":17,"createDept":6,"remark":46,"createTime":47,"children":48,"columnImage":49,"columnLogo":50,"uncheckedLogo":6,"checkedLogo":6,"isHot":17,"isHome":17,"forceLogin":17,"color":6,"seoTitle":51,"seoKeywords":52,"seoDescription":53,"contentNum":6,"promotionalPoster":54,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":55,"routerPath":41,"componentInfo":42},"1986622624134549505","科普视频","video","/video.html","1","0","T","","2025-11-07 10:31:58",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:40/0d7fcb56-3dc4-4dcb-99ca-a5d5c438378e.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:43/958efac7-dd02-4681-b8fd-0dd84b1bbf42.png","健康科普视频大全,了解你的健康生活","健康科普视频, 戒烟视频, 饮食健康视频, 胸痛科普, 用药知识, 职业健康视频, 贫血科普, 眼健康视频","精选健康科普视频,涵盖戒烟、胸痛、饮食、用药与职业健康等多个主题,让你轻松获取科学健康知识,提升生活质量。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:45/fa8fe113-deaa-4454-8105-d629769963dd.png","Video","慢性病,皮肤健康",4,"https://vod.haohuanjiao.com/huanjiao/specialistVideo/864010/a08dc8f4-ede7-4f21-bf62-4df4a9b5d879.tmp?a=0&auth_key=1789007424-cd77fa2f0d2147469b48134aec5f2621-0-b8804bf14c496571b2f5929376516d7a&br=490&bt=490&cd=0%7C0%7C0&ch=0&cr=0&cs=0&dr=0&ds=4&eid=v0247cg10004d2v8gqqljhtc284eagbg&er=0&l=202608110026559653FB07A7DA8A22AE4F&lr=&mime_type=video_mp4&net=0&pl=0&qs=13&rc=ampoO2Zrb3Q7NTczNGY3M0ApZWQ3NXdtdGp5ZzMzajo1eWdfXjEvcWduZHNhLS1kNC9zc2RkYjVgZWluNS8xLS5gMS06Yw%3D%3D&vl=&vr=",true,{"code":9,"msg":58,"message":6,"data":6,"success":59},{"code":9,"msg":10,"message":6,"data":62,"success":59},{"pageNo":30,"pageSize":63,"result":64,"totalSize":17},10,[],{"code":9,"msg":10,"message":6,"data":66,"success":59},{"authors":67,"appraiseDimensionScoresVos":68},[],[]]